Medexus Pharmaceuticals (TSE:MDP) Sets New 1-Year High – What’s Next?

Medexus Pharmaceuticals Inc. (TSE:MDP)’s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as C$3.83 and last traded at C$3.84, with a volume of 84289 shares traded. The stock had previously closed at C$3.60.

Analysts Set New Price Targets

MDP has been the topic of several research analyst reports. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Finally, Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a report on Wednesday. Two investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Strong Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Stock Up 6.7 %

The firm has a fifty day moving average of C$2.74 and a 200-day moving average of C$2.52. The stock has a market capitalization of C$94.20 million, a price-to-earnings ratio of 76.80 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.